Although Rezum and UroLift are widely used minimally invasive treatments for benign prostatic hyperplasia (BPH), long-term comparative evidence remains limited. To address this gap, a study compared 3-year reintervention rates between the two procedures in 3,697 patients aged 40 years or older who underwent Rezum (n=771) or UroLift (n=2,926). Following propensity score matching (PSM), no significant difference was observed in the overall 3-year reintervention rates between the two procedures (hazard ratio [HR], 0.94).
In the subgroup of patients aged 65 years or older, Rezum was associated with fewer reinterventions than UroLift (HR, 0.62). Among those aged 40 to 64 years, Rezum initially appeared to have a higher reintervention rate, but this difference was no longer significant after PSM (HR, 1.23). Within the Rezum cohort, younger patients experienced higher reintervention rates than…
